Particle Engineering Technologies
Solubility is an essential factor for drug effectiveness, independent of administration route. It is also a major challenge for pharmaceutical companies developing new pharmaceutical products since nearly half of all new chemically-based drugs are insoluble, or poorly soluble, in water. Many, otherwise promising, compounds never reach the market. Other compounds reach the market but in a sub-optimal formulation, possibly providing low or unpredictable bioavailability, or posing an increased risk of side effects. Enhanced solubility technology can be used to reformulate such drugs and increase their commercial potential.
The insoluble drug delivery (IDD®), DissoCubes™ and solid lipid nanoparticles (SLN™) technology platforms enhance the uptake and safety of water-insoluble drugs across a broad range of therapeutic classes, including anaesthetics, anti-cancer agents and immunosuppressants.
Copyright 2008, SkyePharma. All Rights Reserved.
SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom
SkyePharma offers two solutions for particle size reduction and particle coating:
- Microfluidizer
- Piston gap HP Homogenizer